Flunixin Meglumine Granules with GMP

• Customization: Available
• Varieties: General Disease Prevention Medicine
• Component: Chemical Synthetic Drugs
• Model NO.: 100g, 200g, 500g, 1kg
• Type: The First Class
• Pharmacodynamic Influential Factors: Combined Medication
• Storage Method: Prevent High or LowTemperature
• Transport Package: Carton
• Specification: 100g, 200g, 500g, 1kg
• Trademark: Customizable
• Origin: China

Product Description

Drug Interactions
(1) Simultaneous use with other non-simplified anti-inflammatory drugs will aggravate the toxic and side effects on the gastrointestinal tract, such as ulcers,Bleeding etc.
(2) Due to the high plasma protein binding rate, when used in combination with other drugs, flunixin meglucose may displace the protein bound to plasma proteins.Other drugs or themselves are replaced by other drugs, so that the effect of the replaced drugs is enhanced or even toxic.
Function and use :
Antipyretic, analgesic and anti-inflammatory drug. Used for febrile, inflammatory diseases, muscle pain and soft tissue pain in small animals.
Usage and dosage:
Based on this product. Oral administration: One dose, 40 mg per kg body weight for dogs and cats, 1 to 2 times a day, continuous use More than days.
Adverse reactions:
Long-term use of large doses of this product may cause gastric ulcer and renal function damage in animals.
Precautions:
Use with caution in animals suffering from digestive tract stains and cancer.
[Drug withdrawal period] :
does not need to be formulated.

Pharmacodynamics:

Flunixin glucoside is a potent cyclooxygenase inhibitor with analgesic, antipyretic, anti-inflammatory and anti-inflammatory properties. The analgesic effect of rheumatism is through inhibiting the synthesis of peripheral prostaglandins or their pain-sensitizing substances or their combined effects, thereby The anti-inflammatory effect of peripheral tissues may be caused by blocking the transmission of pain impulses by inhibiting cyclooxygenase and reducing the form of prostaglandin precursors. It is caused by inhibiting other mediators and causing local inflammatory response. Flunixin meglucose does not affect gastrointestinal motility in horses, but may improve Haemodynamics in animals with septic shock.

Pharmacokinetics:

After a single intramuscular injection in pigs (2.2 mg kg body weight), the plasma elimination half-life is 3 to 4 hours, and the peak concentration is reached. 2. g/mL, the peak time is 0.4 hours, and the drug can still be detected in the blood 18 hours after administration. The apparent volume of distribution is 2.0L/candle, bioavailability of a single neck injection is 87%